The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
17 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $39,079,438 in first-year total cost, median $2,249,392.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ICN-Z (55)]8
- Special Emphasis Panel[ZRG1 IFCN-J (55)]5
- Special Emphasis Panel[ZRG1 ICN-J (55)]4
Most frequent institutions
- NEW YORK UNIVERSITY3
- DUKE UNIVERSITY2
- JOHNS HOPKINS UNIVERSITY2
- STANFORD UNIVERSITY2
- BOSTON CHILDREN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | A fully humanized functional genomic screen to identify and validate pain therapeutic targets1RF1NS142703-01 | PRICE, THEODORE J. | UNIVERSITY OF TEXAS DALLAS, TX | $4,039,366 | ZRG1 |
| 2025 | Targeting Succinate Signaling for Innovative Pain Relief in Oral Cancer.1R01DE035179-01 | LI, XIN | UNIVERSITY OF VIRGINIA, VA | $3,892,146 | ZRG1 |
| 2025 | Determining the function of medium to large diameter sensory neurons in paclitaxel-induced pain via large-scale in vivo DRG imaging1R01CA291906-01A1 | ZHENG, QIN | JOHNS HOPKINS UNIVERSITY, MD | $2,714,830 | ZRG1 |
| 2025 | MicroRNA as a Novel Therapeutic Target for Pain in Sickle Cell Disease1RF1NS143697-01 | HE, YING | MIDWESTERN UNIVERSITY, IL | $1,764,145 | ZRG1 |
| 2024 | Targeting Schwann cell dysfunction and repair signaling in chemotherapy induced painful peripheral neuropathy1R01DE033674-01 | CAMPANA, WENDY M.YE, YI | NEW YORK UNIVERSITY, NY | $2,833,086 | ZRG1 |
| 2024 | Identification and validation of LPA/LPAR signaling as a target for the treatment of temporomandibular disorder pain1R01DE032676-01A1 | CHEN, YONGNACKLEY, ANDREA G | DUKE UNIVERSITY, NC | $2,372,116 | ZRG1 |
| 2024 | Validation of neuronal senescence as a target for chronic pain in aging1RF1AG088052-01 | TAWFIK, VIVIANNE L | STANFORD UNIVERSITY, CA | $2,249,392 | ZRG1 |
| 2024 | Cellular Mechanisms and Therapeutic Potential of NR4A1 in Pain Resolution1RF1NS136108-01 | BERTA, TEMUGIN | UNIVERSITY OF CINCINNATI, OH | $2,103,564 | ZRG1 |
| 2024 | Dissecting the role of mPFC dynorphin circuits in the modulation of different pain states1RF1NS132920-01A1 | SHEETS, PATRICK L | INDIANA UNIVERSITY INDIANAPOLIS, IN | $2,068,842 | ZRG1 |
| 2023 | Targeting checkpoint inhibitors for pain control1RF1NS131812-01A1 | JI, RU-RONG | DUKE UNIVERSITY, NC | $2,569,851 | ZRG1 |
| 2023 | Validation of a new large-pore channel as a novel target for neuropathic pain1RF1NS134549-01 | GUAN, YUNQIU, ZHAOZHU | JOHNS HOPKINS UNIVERSITY, MD | $2,039,202 | ZRG1 |
| 2023 | Validation of Neuropilin-1 Receptor Signaling in Nociceptive Processing1RF1NS131165-01A1 | KHANNA, RAJESH | NEW YORK UNIVERSITY, NY | $95,887 | ZRG1 |
| 2022 | Targeting HB-EGF and trigeminal EGFR for oral cancer pain and opioid tolerance1R01DE032501-01 | YE, YI | NEW YORK UNIVERSITY, NY | $2,389,676 | ZRG1 |
| 2022 | PNPase inhibition as an effective treatment for chronic bladder pain1R01DK135076-01 | BIRDER, LORI AJACKSON, EDWIN KERRY | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $2,371,301 | ZRG1 |
| 2022 | Immune modulating therapies to treat complex regional pain syndrome1RF1NS130481-01 | AJIT, SEENA | DREXEL UNIVERSITY, PA | $2,018,200 | ZRG1 |
| 2022 | Signal integration by specialized mesenchyme in urothelial homeostasis and Interstitial Cystitis / Bladder Pain Syndrome1R01DK134989-01 | BEACHY, PHILIP A | STANFORD UNIVERSITY, CA | $1,799,384 | ZRG1 |
| 2022 | CMG2 as a target for safe and effective treatment of endometriosis-associate pain1R01HD110922-01 | ROGERS, MICHAEL SEAN | BOSTON CHILDREN'S HOSPITAL, MA | $1,758,450 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.